Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.

Cancer metastasis reviews - 1 Sept 2018

Slater K, Hoo P S, Buckley A M, Piulats J M, Villanueva A, Portela A, Kennedy B N

Abstract excerpt

Uveal melanoma is a rare, but deadly, form of eye cancer that arises from melanocytes within the uveal tract. Although advances have emerged in treatment of the primary tumour, patients are still faced with vision loss, eye enucleation and lethal metastatic spread of the disease. Approximately 50% of uveal melanoma patients develop metastases, which occur most frequently in the liver. Metastatic patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinogenesis
Share to Heterografts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Oncogene Proteins

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Identifiers

PMID: 30094568
DOI: 10.1007/s10555-018-9751-z

Genes

CYSLTR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.PMID 30094568Read ↗

High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma CellsSemantic proximity Read ↗

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.Semantic proximity Read ↗

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.Semantic proximity Read ↗

Do ERBB Receptors Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Semantic proximity Read ↗

Genetic and Epigenetic Features of Uveal Melanoma—An Overview and Clinical ImplicationsSemantic proximity Read ↗

Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.Semantic proximity Read ↗

Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.Semantic proximity Read ↗

Pathological and Molecular Diagnosis of Uveal MelanomaSemantic proximity Read ↗

Recent Advances in Molecular and Genetic Research on Uveal Melanoma.Semantic proximity Read ↗

Uveal melanoma: From diagnosis to treatment and the science in between.Semantic proximity Read ↗

Uveal melanoma: progress in molecular biology and therapeuticsSemantic proximity Read ↗

Metastatic uveal melanoma: biology and emerging treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.